Aug. 6, 2025

The ACR® Center for Research and Innovation (CRI®) served as the imaging contract research organization for the DOORwaY90 clinical trial that contributed to FDA approval of Sirtex SIR-Spheres technology for liver cancer treatment.

CRI’s management of image and data collection, quality control, and central review of 600 CT/MRI scans from 65 subjects across 12 sites using five expert reviewers was critical to the success of the trial.

Interim analysis of the DOORwaY90 trial revealed that 98.5% of patients had the Best Overall Response Rate through nine months and 100% of all evaluable patients were able to demonstrate local tumor control.

Related ACR News

  • Feds Propose Revising Small Business Size Standards

    The SBA released a proposed rule to revise the monetary-based small business size standards for 263 industries, including diagnostic imaging centers.

    Read more
  • Deadline Approaches to Fund NIH in FY2026

    ACR members are urged to contact Congress now to support NIH funding and highlight how cuts could harm radiology research and patient care.

    Read more
  • NIH Director States Unified Approach to Institute Operations

    The NIH Director announced a unified approach to advance the agency’s mission to align Institute priorities and funding approaches.

    Read more